Published on Thu Apr 15 2021

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.

Erica J Brenner, Ryan C Ungaro, Richard B Gearry, Gilaad G Kaplan, Michele Kissous-Hunt, James D Lewis, Siew C Ng, Jean-Francois Rahier, Walter Reinisch, Frank M Ruemmele, Flavio Steinwurz, Fox E Underwood, Xian Zhang, Jean-Frederic Colombel, Michael D Kappelman

The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown. We sought to characterize the clinical course of CO VID-19 among patients with IBD and evaluate the association among demographics and immunosuppressant treatments.

1
3
14
Abstract

The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown. We sought to characterize the clinical course of COVID-19 among patients with IBD and evaluate the association among demographics, clinical characteristics, and immunosuppressant treatments on COVID-19 outcomes.